News
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...
Fourteen other states also have created e-cigarette registries like Wisconsin's, according to the Public Health Law Center at Minnesota's Mitchell Hamline School of Law.
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...
6d
Worcester Telegram on MSNNicotine pouches: concerns in Mass. about potential health harms. Here are the detailsSwedish Match, a subsidiary of Philip Morris International, makes the ZYN pouches. The FDA's authorization noted the pouches ...
The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...
1d
Stocktwits on MSNEli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side EffectsEli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...
5d
Axios on MSNZyn nicotine pouches: America's new addictive obsessionAxios Visuals It's not food, it's not chewing tobacco and it's not gum — though it might look like it when you see it — but it is becoming America's new addictive obsession. Why it matters: Sales of ...
Tobacco giant Altria Group is launching a plan to streamline and modernize operations that will involve an unspecified number of layoffs, the Henrico County-based Fortune 500 company disclosed.
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results